These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 9471868)
1. [Epidemiologic indicators of adenocarcinoma of the prostate. Results on 436 patients]. Arrizabalaga Moreno M; García González JI; Diez Rodríguez JM; Esteban Artiaga R; Castro Pita M; Navarro Sebastian J; Mora Durbán M; Paniagua Andrés P Actas Urol Esp; 1997 Oct; 21(9):852-61. PubMed ID: 9471868 [TBL] [Abstract][Full Text] [Related]
2. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis]. Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221 [TBL] [Abstract][Full Text] [Related]
3. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204 [TBL] [Abstract][Full Text] [Related]
5. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
6. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302 [TBL] [Abstract][Full Text] [Related]
7. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452 [TBL] [Abstract][Full Text] [Related]
8. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961 [TBL] [Abstract][Full Text] [Related]
9. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. Tollefson MK; Leibovich BC; Slezak JM; Zincke H; Blute ML J Urol; 2006 Feb; 175(2):547-51. PubMed ID: 16406993 [TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287 [TBL] [Abstract][Full Text] [Related]
11. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764 [TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876 [TBL] [Abstract][Full Text] [Related]
13. A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Green GA; Hanlon AL; Al-Saleem T; Hanks GE Cancer; 1998 Sep; 83(5):971-6. PubMed ID: 9731902 [TBL] [Abstract][Full Text] [Related]
14. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. Hattab EM; Koch MO; Eble JN; Lin H; Cheng L J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733 [TBL] [Abstract][Full Text] [Related]
15. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Ryan CJ; Elkin EP; Small EJ; Duchane J; Carroll P Urol Oncol; 2006; 24(5):396-402. PubMed ID: 16962488 [TBL] [Abstract][Full Text] [Related]
16. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301 [TBL] [Abstract][Full Text] [Related]
17. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435 [TBL] [Abstract][Full Text] [Related]
18. [Analysis of a series of radical prostatectomies]. Rioja Sanz LA; Liedana Torres JM; Roncales Badal A; Gil Sanz MJ; Villanueva Benedicto A; Rodríguez Vela L; Gil Martínez P Actas Urol Esp; 1997 Oct; 21(9):809-16. PubMed ID: 9471862 [TBL] [Abstract][Full Text] [Related]
19. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cheng L; Davidson DD; Lin H; Koch MO Cancer; 2007 Nov; 110(9):1967-72. PubMed ID: 17823907 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]